Triple Threat Communications: 2024
While maintaining its client-first focus in everything they do, TTC deepened its relationships with existing clients, developed new ones, and began to reimagine its future in new and exciting ways.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
The Value Builders: 2024
/in April 2024, Healthcare Communications Agencies, Issue Archives, Marketing & Advertising/by Administrator“After our official launch in 2020, we have nearly tripled in size, representing more than 40 employees and delivering our best financial year ever. As a key component of The Bloc’s Global Vision, The Value Builders embarked on an ambitious plan to continue servicing clients at the highest possible level, while adding to the full-service market access capabilities our clients need.”
VML Health: 2024
/in April 2024, Healthcare Communications Agencies, Issue Archives, Marketing & Advertising/by AdministratorIn 2023, VMLY&R Health and Wunderman Thompson Health merged to create VML Health, which agency leaders say is one of the largest and most comprehensive health communications networks in North America and the world.
YuzuYello: 2024
/in April 2024, Healthcare Communications Agencies, Marketing & Advertising/by Administrator“As a specialty agency within that network, we at YuzuYello have layered our mission onto that bedrock. We build brighter worlds for the people our brands serve, our clients and each other.”
Bavarian Nordic’s mpox vaccine safe, effective at lower doses: study
/in R&D, Therapeutics/by BioSpaceA Phase II study funded by the National Institutes of Health found that a dose-sparing, intradermal regimen of Bavarian Nordic’s intradermal mpox vaccine Jynneos (modified vaccinia Ankara-Bavarian Nordic) can match the antibody response elicited by the standard-dose regimen.
US FDA approves X4 Pharmaceuticals’ therapy for immunodeficiency disease
/in Therapeutics/by Reuters HealthX4’s mavorixafor, to be sold under the brand name Xolremdi, is the first therapy to get U.S. approval specifically for the treatment of WHIM syndrome.
What’s next for obesity therapeutics? Higher quality weight loss
/in Therapeutics/by BioSpaceWith GLP-1 agonists slated to become the best-selling drugs in 2024, the biopharma industry is already pivoting to explore treatments that preserve muscle mass as patients shed pounds.
Five mid-stage ALS drugs to watch
/in Therapeutics/by BioSpaceAfter a years-long drought, progress in the amyotrophic lateral sclerosis (ALS) space began to accelerate with the 2022 approval of Amylyx’s Relyvrio and Biogen and Ionis’ Qalsody in 2023. But now, that progress appears to have stalled. Earlier this month, Amylyx announced it would pull Relyvrio from the market after a failed Phase III trial, and closely watched trials from Seelos Therapeutics and Sanofi and Denali Therapeutics recently missed their primary endpoints.
Morphosys says takeover by Novartis on course after report of drug safety concern
/in Therapeutics/by Reuters HealthMorphosys’ statement came after a report that cited two people familiar with the matter, of a safety issue with its experimental drug pelabresib, which is being developed to treat myelofibrosis, a rare type of blood cancer affecting the bone marrow.
Philips shares surge on US recall settlement news
/in Therapeutics/by Reuters HealthPhilips said it had agreed to pay $1.1 billion to settle all personal injury claims filed in the U.S., ending uncertainty that had slashed its market value over the past three years.